Navigation Links
Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
Date:11/3/2010

NEWTON, Mass., Nov. 3, 2010 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $20M Series A financing. The nuclear transport machinery plays an integral role in the regulation of many molecules involved in a broad spectrum of human and animal disease. Karyopharm is focused on the discovery and development of novel selective inhibitors of nuclear export (SINE) for the treatment of cancer, autoimmune diseases and HIV.  These SINEs act by forcing the nuclear localization of major tumor suppressor and growth regulatory proteins, causing selective death of cancer cells, while sparing normal cells. The Karyopharm platform, utilizing rapid chemical optimization with integrated computational/in silico rational drug design, has yielded multiple novel active small molecule SINEs, which have shown activity in animal models of cancer.

The Series A financing, which follows approximately $1M in Angel investments, will be used to expand Karyopharm's research and development platform and to drive its first drug candidates into the clinic.  Sharon Shacham, PhD, MBA, Karyopharm's CSO and Acting President, remarked, "With this financing, we are able to move decisively to select a clinical candidate for our first indication in cancer. We believe that SINEs represent a completely new and highly effective approach to the treatment of cancers and other diseases with major unmet need.  Preclinical studies of our advanced SINEs have shown impressive single agent activity and synergy in combination with specific anti-cancer drugs while exhibiting good tolerability in animal models."

By inhibiting the nuclear export of tumor suppressor proteins, Karyopharm's drug candidates force the activation of the cell's own key regulatory pathways including those activated by p53, p27, pRB, BRACA1/2, FoxO, and the inhibitor of NF-kB (i.e., IkB). According to Karyopharm Co-Founder, Ronald A. DePinho, M.D., "The targeting of single molecules have provided marginal advances in cancer.  By blocking the export of multiple tumor suppressor proteins, this strategic point of intervention can impact on multiple pathways which cooperate to maintain tumors.  As normal cells want to keep these proteins in the nucleus, these SINEs should also exhibit an excellent safety profile in patients."

Following the Series A investment, Drs. Mansoor Raza Mirza, Ronald DePinho, and Michael Kauffman will comprise the Board of Directors.  Dr. Mirza, M.D. is Chief Oncologist at the Department of Oncology, Rigshospitalet - the Copenhagen University Hospital, Denmark.  Dr. DePinho is the Director of the Belfer Institute for Applied Cancer Science and Professor of Medicine and Genetics at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Giulio Draetta, M.D., Ph.D., a leader in cancer drug development, is Deputy Director of the Belfer Institute and Chief Research Business Officer at the Dana-Farber Cancer Institute.  Dr. Draetta will chair the Scientific Advisory Board.

About Karyopharm Therapeutics Inc.

Karyopharm is a privately held oncology company headquartered in Newton, Massachusetts. The Company was founded in 2009 by Drs. Sharon Shacham, Michael Kauffman, Ronald DePinho, and Giulio Draetta.  Karyopharm's founding team and scientific advisory board have demonstrated entrepreneurial success in developing project ideas to productive clinical outcomes. The company is focused on the development of modulators of nuclear transport as novel therapies for cancer, inflammatory and other diseases.  With the recent determination of the 3-dimensional structure of the nuclear pore complex, the mechanisms of nuclear transport have become more apparent.  Many key tumor suppressor and growth regulatory proteins are exported from the nucleus by the major export protein CRM1. Using its proprietary computational chemistry platform, Karyopharm has rapidly discovered and optimized a series of selective inhibitors of nuclear export (SINE) targeting the CRM1 protein.  Additional programs focused on other aspects of nuclear export, as well as nuclear import, have been initiated.

http://www.karyopharm.com

Contact: mkauffman@karyopharm.com


'/>"/>
SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
2. Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program
3. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
4. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
5. Shield Therapeutics Signs Agreement With AOP Orphan for ST10-021
6. Echo Therapeutics to Present at the LifeTech Capital 1st Annual Miami Medical Investors Conference
7. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
8. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
9. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
10. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
11. Cell Therapeutics Third Quarter Net Loss Decreases by 68% in 2010 Compared to 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Maharashtra, February 12, 2016 ... Market research report titled Chronic Inflammation Global Clinical ... a snapshot of the global clinical trials landscape ... clinical trials by Region, Country (G7 & E7), ... point status and reviews top companies involved and ...
(Date:2/11/2016)... Feb. 11, 2016 Stem cells are primitive ... by self-renewal and the capacity to differentiate into mature ... discovery, as the first mouse embryonic stem cells were ... until 1995 that the first culturing of embryonic stem ... were not produced until 2006 As a result of ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... ... Society (INS) states that vein visualization technology should be used to ensure patient ... around the world, the INS Standards mandate the use of vein visualization technology ...
(Date:2/13/2016)... ... 13, 2016 , ... When an Au Pair comes all the way around the ... in for and they are often worried things won’t go well. More often than not, ... year’s Au Pair of the Year winner’s all commented how their Au Pairs have become ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi ... Management Solution Providers list for its expertise in eClinical Solutions. DDi has built ... serve the technology needs of global clients. DDi provides smarter technology for Clinical ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Mystic Buddha Publishing ... in Blue SKies Buddha, the biography of Rama - Dr. Frederick Lenz. ... story, the love of a Buddhist teacher for teaching and helping others. Valentine’s ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to introduce ... from U.S. universities who will draw from Siemens’ deep knowledge of product ...
Breaking Medicine News(10 mins):